Batch prepared protein standards for cerebrospinal fluid (CSF) biomarkers for neurodegeneration

Journal of Neuroscience Methods

Volumn 193, Issue 2, 2010, Pages 296-299

  Petzold, A ^a   Verwey, N A ^a,b   van Uffelen, K ^a   Blankenstein, M A ^a   Teunissen, C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biomarker; Standard curve; Validation

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; TAU PROTEIN;

ACCURACY; ALZHEIMER DISEASE; ANALYTIC METHOD; ARTICLE; CEREBROSPINAL FLUID; DIAGNOSTIC TEST; HUMAN; IMMUNOASSAY; LIGHT CHAIN; NERVE DEGENERATION; NEUROFILAMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN CEREBROSPINAL FLUID LEVEL; QUANTITATIVE ANALYSIS; STANDARDIZATION; VALIDATION PROCESS; VALIDATION STUDY;

AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; HUMANS; IMMUNOASSAY; LINEAR MODELS; NERVE DEGENERATION; PEPTIDE FRAGMENTS; QUALITY CONTROL; REFERENCE VALUES; STATISTICS, NONPARAMETRIC; TAU PROTEINS;

EID: 78049378827     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2010.08.028     Document Type: Article

References (16)

1. Bibl M., Esselmann H., Otto M., Lewczuk P., Cepek L., Rther E., et al. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. Electrophoresis 2004, 25(17):2912-2918.
2. Bland J., Altman D. Measuring agreement in method comparison studies. Stat Methods Med Res 1999, 8:135-160.
3. Blennow K., Hampel H., Weiner M., Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010, 6(3):131-144.
4. Carraro P., Plebani M. Errors in a stat laboratory: types and frequencies 10 years later. Clin Chem 2007, 53:1338-1342.
5. Lewczuk P., Beck G., Esselmann H., Bruckmoser R., Zimmermann R., Fiszer M., et al. Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. Clin Chem 2006, 52(2):332-334.
6. Lewczuk P., Beck G., Ganslandt O., Esselmann H., Deisenhammer F., Regeniter A., et al. International quality control survey of neurochemical dementia diagnostics. Neurosci Lett 2006, 409(1):1-4.
7. Mattsson N., Blennow K., Zetterberg H. Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. Clin Chem Lab Med 2010, 48(5):603-607.
8. Mattsson N., Zetterberg H., Hansson O., Andreasen N., Parnetti L., Jonsson M., et al. Csf biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009, 302(4):385-393.
9. Mulder C., Verwey N.A., van der Flier W.M., Bouwman F.H., Kok A., van Elk E.J., et al. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 2010, 56(2):248-253.
10. Petzold A., Altintas A., Andreoni L., Bartos A., Berthele A., Blankenstein M.A., et al. Neurofilament ELISA validation. J Immunol Methods 2010, 352:23-31.
11. Petzold A., Chapman M.D., Schraen S., Verwey N.A., Pasquier F., Bombois S., et al. An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels. Exp Neurol 2009, (223):432-438.
12. Pitschke M., Prior R., Haupt M., Riesner D. Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nat Med 1998, 4(7):832-834.
13. Simonsen A.H., Hansson S.F., Ruetschi U., McGuire J., Podust V.N., Davies H.A., et al. Amyloid beta1-40 quantification in csf: comparison between chromatographic and immunochemical methods. Dement Geriatr Cogn Disord 2007, 23(4):246-250.
14. Teunissen C., Dijkstra C., Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 2005, 4:32-41.
15. Teunissen C.E., Petzold A., Bennett J.L., Berven F.S., Brundin L., Comabella M., et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009, 73(22):1914-1922.
16. Verwey N., van der Flier W., Blennow K., Clark C., Sokolow S., De Deyn P., et al. A worldwide multicenter comparison of assays for CSF biomarkers in Alzheimer disease. Ann Clin Biochem 2009, 46:235-240.